- Home
- WAVE vs CUE Comparison
WAVE vs CUE Comparison
Compare WAVE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WAVE | CUE |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 27.8M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WAVE | CUE |
|---|---|---|
| Price | $7.07 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 9.0K | ★ 717.6K |
| Earning Date | 03-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $1,913.16 | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $4.51 | $0.23 |
| 52 Week High | $9.85 | $1.05 |
Technical Indicators
Market Signals| Indicator | WAVE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 39.51 |
| Support Level | $5.72 | $0.23 |
| Resistance Level | $7.11 | $0.45 |
| Average True Range (ATR) | 0.49 | 0.03 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 73.12 | 14.69 |
Price Performance
Historical ComparisonAbout WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.